Infigratinib was also compared to gemcitabine plus cisplatin as a front-line setting in patients with advanced or metastatic CCA with FGFR2 gene fusion/translocation in the phase III PROOF trial (NCT03773302). Here, FGFR2 is linked to cholangiocarcinoma.